Achieve Life Sciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Achieve Life Sciences, Inc.
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
A confluence of factors promoting the rapid adoption of health care AI is expected to make 2021 a pivotal year for the technology, as demonstrated by product launches at RSNA 2020.
Artificial intelligence (AI) vendors are partnering with health care providers to identify practical challenges and consider AI technology as a potential solution. This type of collaboration is crucial to successful AI adoption because the technology is designed to tackle real-world health care problems. A myriad of examples was displayed at the recent RSNA 2020 meeting.
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- OncoGenex Pharmaceuticals, Inc.
- Sonus Pharmaceuticals, Inc.